Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence

Authors Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM

Received 25 October 2012

Accepted for publication 10 December 2012

Published 17 January 2013 Volume 2013:9 Pages 3—11

DOI https://doi.org/10.2147/VHRM.S39571

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Caleb Ferguson,1 Sally C Inglis,1 Phillip J Newton,1 Sandy Middleton,2,3 Peter S Macdonald,3,4 Patricia M Davidson1,3

1Center for Cardiovascular and Chronic Care, University of Technology, 2National Center for Clinical Outcomes Research (NaCCOR), Australian Catholic University, 3St Vincent's Hospital, Darlinghurst, Sydney, Australia; 4Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia

Abstract: Atrial fibrillation is a common arrhythmia in heart failure and a risk factor for stroke. Risk assessment tools can assist clinicians with decision making in the allocation of thromboprophylaxis. This review provides an overview of current validated risk assessment tools for atrial fibrillation and emphasizes the importance of tailoring individual risk and the importance of weighing the benefits of treatment. Further, this review provides details of innovative and patient-centered methods for ensuring optimal adherence to prescribed therapy. Prior to initiating oral anticoagulant therapy, a comprehensive risk assessment should include evaluation of associated cardiogeriatric conditions, potential for adherence to prescribed therapy, frailty, and functional and cognitive ability.

Keywords: stroke risk, heart failure, atrial fibrillation, anticoagulation, risk stratification, medication adherence

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Congenital anomaly of the inferior vena cava and factor V Leiden mutation predisposing to deep vein thrombosis

Lamparello BM, Erickson CR, Kulthia A, Virparia V, Thet Z

Vascular Health and Risk Management 2014, 10:609-613

Published Date: 4 November 2014

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

Dardano A, Bianchi C, Del Prato S, Miccoli R

Vascular Health and Risk Management 2014, 10:465-475

Published Date: 5 August 2014

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR

Vascular Health and Risk Management 2014, 10:237-246

Published Date: 25 April 2014

Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria

Dodiyi-Manuel ST, Akpa MR, Odia OJ

Vascular Health and Risk Management 2013, 9:529-533

Published Date: 25 September 2013

Current status of NADPH oxidase research in cardiovascular pharmacology

Rodiño-Janeiro BK, Paradela-Dobarro B, Castiñeiras-Landeira MI, Raposeiras-Roubín S, González-Juanatey JR, Álvarez E

Vascular Health and Risk Management 2013, 9:401-428

Published Date: 25 July 2013

Effects of low-fat dairy intake on blood pressure, endothelial function, and lipoprotein lipids in subjects with prehypertension or stage 1 hypertension

Maki KC, Rains TM, Schild AL, Dicklin MR, Park KM, Lawless AL, Kelley KM

Vascular Health and Risk Management 2013, 9:369-379

Published Date: 23 July 2013

The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report

Ferrario CM, Joyner J, Colby C, Exuzides A, Moore M, Simmons D, Bestermann Jr W, Frech-Tamas F

Vascular Health and Risk Management 2013, 9:391-400

Published Date: 22 July 2013

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E

Vascular Health and Risk Management 2013, 9:207-228

Published Date: 8 May 2013

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013